

Please type a plus sign (+) inside this box

JUN 01 2005

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

Approved for use through 10/31/2017. GSA ECR #2017-003.
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete If Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Shee

1

11

1

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name _____


Attorney Docket Number **SCH-1615-D01**

Attorney Docket Number | SCH-1615-D01

ENT DOCUMENTS

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	6-19-05
--------------------	---	-----------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	09/471,040
Filing Date	12/23/1999
First Named Inventor	TILSTAM, Ulf et al.
Group Art Unit	1623
Examiner Name	OWENS, Jr., Howard V.

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
HO	C1	Notice of Opposition to European Patent No. 1 047 704, Application No. 98965703.6, Mayne Pharma Pty, Ltd., Date of Mention 01/29/2003.
HO	C2	Declaration of Donald Corcoran, dated 10/27/2003.
HO	C3	Letter from Alltech Association Australia Pty, Ltd., dated 10/22/2003 with declaration attached from Dr. Phillip J. Anevski, dated 10/23/2003.
HO	C4	Letter from Boult Wade Tennant dated 10/29/2003.
HO	C5	The Nucleic Acids Chemistry and Biology, Volume 1, 1955, chapter 6, pages 211 - 241.
HO	C6	Exhibit C, Fludarabine Phosphate >99.5% Pure After Dowex 1X4 Column, 7/24/2003, with attached, Waldo E. Cohn, The Anion-Exchange Separation of Ribonucleotides, 72 J. Am. Chem. Soc., pp. 1471 - 1478 (1950)
HO	C7	Waldo E. Cohn, Methods of Isolation and Characterization of Mono and Polynucleotides by Ion Exchange Chromatography, 107 Methods in Enzymology, pp. 724 - 743 (1967).
HO	C8	In the House of Lords, Biogen Inc. v. Medeva PLC, dated October 31, 1996, pages 1 - 54.
HO	C9	Henry Herbert Cobb III, Stability of Fludarabine Phosphate, Pentostatin, and Amsacrine in Commonly Used Infusion Solutions and After Filtration, and Osmolality of Various Constituted Chemotherapeutic Agents, pp. 20 - 48 (1995).
HO	C10	Boards of Appeal of The European Patent Office, Decision, Previously Presented. 20 - 48, Case No. T 0990/96 - 3.3.1. (02/12/1998)
HO	C11	The MERCK Index, Twelfth Edition, 1996. <i>Fludarabine</i>
HO	C12	Official Monographs, USP 26, Fludarabine Phosphate, pages 3096 - 3097 (1996).
HO	C13	U.S. Schering's Reply
HO	C14	Notice of Opposition to European Patent No. EP 1047704, App. No. 98965703.6, by Curtis, Phillip Anthony, 11/11/2003.
HO	C15	Notice of Opposition to European Patent No. EP 1047704, App. No 98965703.6, by Sicor, Inc., Date of Mention 1/29/2003.
HO	C16	EP-B-1047704 Opposition by SICOR Inc., in European Patent No. 1047704, App. No. 98965703.6, Experimental Report, dated 10/29/2003.
HO	C17	PGT Report for App. No. PCT/EP98/07651, dated 1/27/05.

Examiner
Signature

Date
Considered

6-10-05

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.